tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Jan 19;S1201-9712(22)00032-7.
doi: 10.1016/j.ijid.2022.01.031. Online ahead of print.
Case report: Acute exacerbation of interstitial pneumonia related to mRNA COVID-19 vaccination
Saori Amiya[SUP] 1 [/SUP], Jun Fujimoto[SUP] 2 [/SUP], Kinnosuke Matsumoto[SUP] 1 [/SUP], Makoto Yamamoto[SUP] 1 [/SUP], Yuji Yamamoto[SUP] 1 [/SUP], Midori Yoneda[SUP] 1 [/SUP], Tomoki Kuge[SUP] 1 [/SUP], Kotaro Miyake[SUP] 1 [/SUP], Takayuki Shiroyama[SUP] 1 [/SUP], Haruhiko Hirata[SUP] 1 [/SUP], Yoshito Takeda[SUP] 1 [/SUP], Atsushi Kumanogoh[SUP] 3 [/SUP]
Affiliations
Abstract
mRNA vaccines that protect against coronavirus disease (COVID-19) are widely used in many countries due to their high efficacy and safety profiles. Recently, some severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy individuals. The safety of mRNA COVID-19 vaccines has not been adequately studied in patients with interstitial lung disease. We report two cases of acute exacerbation of pre-existing interstitial pneumonia associated with mRNA COVID-19 vaccination. In both cases, lung disease was stable prior to the vaccination. Initial responses to steroid therapy were unfavorable, and intravenous cyclophosphamide was administered in both cases. Both patients were diagnosed with vaccine-related exacerbation of interstitial pneumonia, based on laboratory results, radiological features, and the observed clinical course, which lacked other causative events. We suggest that clinicians should note the possibility of acute exacerbation of pneumonia after mRNA COVID-19 vaccination, and carefully monitor patients with interstitial lung disease.
Keywords: COVID-19; SARS-CoV-2; acute exacerbation of interstitial pneumonia; case report; mRNA vaccine.
. 2022 Jan 19;S1201-9712(22)00032-7.
doi: 10.1016/j.ijid.2022.01.031. Online ahead of print.
Case report: Acute exacerbation of interstitial pneumonia related to mRNA COVID-19 vaccination
Saori Amiya[SUP] 1 [/SUP], Jun Fujimoto[SUP] 2 [/SUP], Kinnosuke Matsumoto[SUP] 1 [/SUP], Makoto Yamamoto[SUP] 1 [/SUP], Yuji Yamamoto[SUP] 1 [/SUP], Midori Yoneda[SUP] 1 [/SUP], Tomoki Kuge[SUP] 1 [/SUP], Kotaro Miyake[SUP] 1 [/SUP], Takayuki Shiroyama[SUP] 1 [/SUP], Haruhiko Hirata[SUP] 1 [/SUP], Yoshito Takeda[SUP] 1 [/SUP], Atsushi Kumanogoh[SUP] 3 [/SUP]
Affiliations
- PMID: 35065256
- DOI: 10.1016/j.ijid.2022.01.031
Abstract
mRNA vaccines that protect against coronavirus disease (COVID-19) are widely used in many countries due to their high efficacy and safety profiles. Recently, some severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy individuals. The safety of mRNA COVID-19 vaccines has not been adequately studied in patients with interstitial lung disease. We report two cases of acute exacerbation of pre-existing interstitial pneumonia associated with mRNA COVID-19 vaccination. In both cases, lung disease was stable prior to the vaccination. Initial responses to steroid therapy were unfavorable, and intravenous cyclophosphamide was administered in both cases. Both patients were diagnosed with vaccine-related exacerbation of interstitial pneumonia, based on laboratory results, radiological features, and the observed clinical course, which lacked other causative events. We suggest that clinicians should note the possibility of acute exacerbation of pneumonia after mRNA COVID-19 vaccination, and carefully monitor patients with interstitial lung disease.
Keywords: COVID-19; SARS-CoV-2; acute exacerbation of interstitial pneumonia; case report; mRNA vaccine.